Search
for
Sort by
Research 421–450 of 1000+
- Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
- Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights
- Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
- Administration Of 45% Robusta (Coffea canephora) Green Coffee Bean Ethanol Extract Solution Could Not Increased Hair Growth But Inhibited The Increase Of 5α-Reductase Type 1 Levels In Male Wistar Rats (Rattus norvegicus) Exposed To Topical Testosterone
- Efficacy and safety of α-blockers plus 5α-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis
- Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride
- 4‐MAPC, a 5α‐Reductase Inhibitor, Reduces Rat Ventral Prostate Weight, DNA, and Prostatein Concentrations
- Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
- Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Association of breast cancer in men with exposure to 5-α reductase inhibitors: A RADAR report.
- Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
- The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
- Quality-of-life changes in women with female androgenetic alopecia treated with a methylsulfonylmethane-containing 5-alpha-reductase inhibitor: a clinical practice study
- Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors
- Ligand Based 3D-QSAR Study on a Series of Steroidal Human 5α-Reductase Inhibitors
- Synthesis, Biological Evaluation and in silico Studies of Novel 5α-aza-Bhomo-3,5-secosteroids as Potential 5-reductase Inhibitors
- 9 Role of 5α-reductase in health and disease
- Nipple Differentiation in Fetal Male Rats Treated with an Inhibitor of the Enzyme 5<i>α</i>-Reductase: Definition of a Selective Role for Dihydrotestosterone*
- Immunolocalization of 5α-Reductase Isozymes in Acne Lesions and Normal Skin
- Anabolic effects of testosterone are preserved during inhibition of 5α-reductase
- 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
- 5α-reductase inhibitors impact prognosis of urothelial carcinoma
- 5α‐Reductase inhibitors and prostatic disease
- 5α-Reductase Inhibitory Components as Antiandrogens From Herbal Medicine
- Development of a new gas chromatography–mass spectrometry (GC–MS) methodology for the evaluation of 5α-reductase activity